PTEN and non-small cell lung carcinoma: The correlation between Erlotinib and Gefitinib sensitivity is excellent as described by Gandhi and colleagues who also showed in a large preclinical study comprising 77 NSCLC lines that all sensitive cell lines (IC50 below 1 μM) had activating mutations or copy number gains but no secondary resistance mutations like T790M or PTEN loss.